ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2169

Cost-utility of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-economic Analysis of the Towards the Lowest Efficacious Dose Trial

Joanna Kedra1, Benjamin Granger2, Lina El Houari3, Florence Tubach4 and Bruno Fautrel5, 1Sorbonne Université, IPLESP, and Pitié-Salpêtrière Hospital, Paris, France, 2Sorbonne Université, INSERM, and Pitié Salpêtrière Hospital, Paris, France, 3Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France, 4Centre de pharmaco-épidémiologie de l'APHP, Paris, France, 5Sorbonne Université APHP, Paris, France

Meeting: ACR Convergence 2023

Keywords: Biologicals, Economics, Health Services Research, Randomized Trial, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2141–2176) RA – Treatments Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) progressive tapering is a real opportunity in people living with rheumatoid arthritis (RA) having achieved remission both from the patient (reduction in the disease and drug-related burden) and the Society (cost alleviation) perspectives. The ToLEDo (Towards the Lowest Efficacious Dose) trial aimed to assess a disease activity-driven progressive tapering strategy of tocilizumab (TCZ) or abatacept (ABA) compared to their maintenance at full dose in RA patients in sustained remission. Non-inferiority (NI) was not demonstrated in terms of disease activity nor relapses, major relapses, radiographic progression. The aim of this secondary analysis was to assess the cost-utility of the spacing strategy (S-arm) in the ToLEDo trial compared to full dose maintenance (M-arm).

Methods: ToLEDo is a multicenter 2-year NI randomized open-label controlled trial, which enrolled 228 patients (113 in the S-arm and 115 in the M-arm). A cost-utility analysis was conducted on the per protocol population. In each arm, health benefits were estimated every 6 months by Short Form Health Survey (SF-6D) and EuroQoL (EQ-5D)-derived utility measurements. Cost elicitation integrated health resource use including bDMARD costs (direct cost) as well as productivity loss (indirect cost).The incremental cost-utility ratios (ICUR) were calculated by dividing the difference of costs between S-arm and M-arm by the difference of utilities between the 2 arms. 95% confidence interval (95%CI) were calculated by bootstrap (20,000 iterations). The incremental net benefit (INB) was calculated for willingness to pay (WTP) values ranging from 0 to 150,000€. The analyses were replicated using SF-6D (primary analysis) or EQ-5D, and in ABA and TCZ subgroups. Acceptability analyses as well as stochastic sensitivity analyses (simulating costs and utilities using MCMC algorithms) were also performed.

Results: Overall, 178 patients were included (82 in S-arm, 96 in M-arm) in the per protocol analysis. At the end of the follow-up in the S-arm, 15.0% of patients discontinued their biologic, 48.7% spaced the injections, and 36.3% remained at the standard dose. The difference in terms of two-years utility gains between S-arm and M-arm was 0.004 (95%CI -0.012, 0.021) with SF-6D. The difference of total costs between S-arm and M-arm was -4,275 € (95%CI -5,955 to -2,542). The estimated ICUR of the spacing strategy over the maintenance at full dose was €932,003 saved per QALY (95% CI -7,534,788 to 6,720,372) with SF-6D. The INB was 4,734.6€ for a WTP of 100,000€. With a willingness to accept of 0 €/QALY lost, the probability to be cost-effective for the spacing strategy was 70.6% (Figure 1). The results were consistent when using EQ-5D-derived utilities, in ABA and TCZ subgroups, as well as in the stochastic sensitivity analyses (Table 1).

Conclusion: Although the ToLEDo trial did not demonstrate non-inferiority, the tested disease activity-driven tapering strategy was not associated with health loss in terms of utilities and incurred for substantial cost savings, making this strategy potentially dominant.

Supporting image 1

Figure 1: cost-utility plane (spacing versus maintenance), with utilities derived from PP SF-6D

Supporting image 2

Table 1: ICUR in ABA subgroup, TCZ subgroup, using EQ-5D-derived utilities, and stochastic sensitivity analysis


Disclosures: J. Kedra: Amgen, 12, Hospitality, Bristol-Myers Squibb(BMS), 6, Galapagos, 2, Roche, 2; B. Granger: Bristol-Myers Squibb(BMS), 2; L. El Houari: None; F. Tubach: Lundbeck, 2, Merck/MSD, 2, UCB, 2; B. Fautrel: AbbVie, 2, BMS, 2, Chugai, 2, Fresenius Kabi, 2, Galapagos, 2, Lilly, 2, Medac, 2, Nordic Pharma, 2, Novartis, 2, Pfizer, 2, Sobi, 2, UCB, 2.

To cite this abstract in AMA style:

Kedra J, Granger B, El Houari L, Tubach F, Fautrel B. Cost-utility of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-economic Analysis of the Towards the Lowest Efficacious Dose Trial [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/cost-utility-of-a-progressive-spacing-of-tocilizumab-or-abatacept-in-patients-with-rheumatoid-arthritis-in-sustained-remission-a-medico-economic-analysis-of-the-towards-the-lowest-efficacious-dose-tr/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cost-utility-of-a-progressive-spacing-of-tocilizumab-or-abatacept-in-patients-with-rheumatoid-arthritis-in-sustained-remission-a-medico-economic-analysis-of-the-towards-the-lowest-efficacious-dose-tr/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology